The present disclosure relates to nanoemulsion compositions with certain surfactant blend ratios that impart enhanced permeability. Such compositions are useful for topical, mucosal, vaginal, and intranasal applications and allow for the greater delivery of one or more active agents to the application site.

The present disclosure relates to nanoemulsion compositions with certain surfactant blend ratios that impart enhanced permeability. Such compositions are useful for topical, mucosal, vaginal, and intranasal applications and allow for the greater delivery of one or more active agents to the application site.

Disclosed herein are bacteria-based HIV MPER vaccine candidates, as well as bacteria-based candidates for other viruses and for bacteria. The HIV vaccine candidates express MPER-derived antigens on their surfaces using Gram autotransporters. The surface-expressed MPER antigens bind several different MPER-directed anti-HIV Broadly Neutralizing Monoclonal Antibodies. When the bacteria expressing the MPER-derived antigens on their surfaces are used to immunize mice they elicit the production of sera and vaginal wash material that bind the bacteria expressing the MPER antigens. At least one of the bacteria expressing MPER-derived antigens on their surfaces elicits the production of sera with anti-HIV neutralizing activity. Killed whole cell and live Salmonella expressing the MPER derived antigens on their surfaces constitute new approaches to HIV vaccine develop that is plausible and that could ultimately yield an inexpensive, globally appropriate candidate vaccine that could be rapidly produced and deployed largely using currently available technology.

Disclosed herein are bacteria-based HIV MPER vaccine candidates, as well as bacteria-based candidates for other viruses and for bacteria. The HIV vaccine candidates express MPER-derived antigens on their surfaces using Gram autotransporters. The surface-expressed MPER antigens bind several different MPER-directed anti-HIV Broadly Neutralizing Monoclonal Antibodies. When the bacteria expressing the MPER-derived antigens on their surfaces are used to immunize mice they elicit the production of sera and vaginal wash material that bind the bacteria expressing the MPER antigens. At least one of the bacteria expressing MPER-derived antigens on their surfaces elicits the production of sera with anti-HIV neutralizing activity. Killed whole cell and live Salmonella expressing the MPER derived antigens on their surfaces constitute new approaches to HIV vaccine develop that is plausible and that could ultimately yield an inexpensive, globally appropriate candidate vaccine that could be rapidly produced and deployed largely using currently available technology.

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

An immunogenic composition comprising at least one Norovirus antigen and at least one adjuvant which is at least one B subunit of an AB.sub.5 toxin such as cholera toxin subunit B (CTB) or the B subunit of heat-labile E. coli exotoxin LT (LTB).

An immunogenic composition comprising at least one Norovirus antigen and at least one adjuvant which is at least one B subunit of an AB.sub.5 toxin such as cholera toxin subunit B (CTB) or the B subunit of heat-labile E. coli exotoxin LT (LTB).

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

This disclosure relates to multivalent enterovirus vaccine compositions and uses related thereto. In certain embodiments, the disclosure relates to vaccine compositions comprising multivalent, mixtures of enterovirus (for example HRV) serotypes or recombinantly produced variants or recombinantly produced viral capsid proteins. In certain embodiments, the disclosure relates to methods of immunization comprising administering an effective amount of compositions disclosed herein to a subject diagnosed with, exhibiting symptoms of, or at risk of an enterovirus infection.